¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2022-04-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2022-04-29
±³À°ÀÏÀÚ : 2022-04-29
±³À°Àå¼Ò : ¿Â¶óÀΠ 
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ
´ã´çÀÚ : ¹Ú¼Ò¹Î
¿¬¶ôó : 02-398-5055  
À̸ÞÀÏ : office@kscpt.org      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¸¶ÃëÅëÁõÀÇÇаú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã 
±³À°½Ã°£ : 4 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í ¿Â¶óÀÎ Âü¼® : Á¤È¸¿ø 5¸¸¿ø, ÁØȸ¿ø 2¸¸¿ø / ºñȸ¿ø ÀÏ¹Ý 10¸¸¿ø, ºñȸ¿ø Çлý 5¸¸¿ø  ÇöÀåÂü¼® : Á¤È¸¿ø 7¸¸¿ø, ÁØȸ¿ø 4¸¸¿ø / ºñȸ¿ø ÀÏ¹Ý 12¸¸¿ø, ºñȸ¿ø Çлý 8¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ13:00~13:40 Special lecture : Facts and Misconceptions about Aducanumab Approval  Yaning Wang(Createrna Science and Technology) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ13:40~14:10 Model guided dose escalation in oncology Phase 1 trial  ±èÀ翬(Novartis Institutes for Biomedical Research (Cambridge MA USA)) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ14:10~14:40 Exposure-response relationship for current and future drug development  ¿ÀÀ缺(¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ14:40~15:10 Recent advances in exposure-response relationship in drug development  ±èÁ¾·ü(ÀÎÁ¦´ë ºÎ»ê¹éº´¿ø) 
Åä·Ð 04-29 ¿Â¶óÀΠ15:10~15:30 Åä·Ð  () 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ15:30~16:00 Exposure-Response in Cancer: Starting from Genomics  ±è±ÔÇ¥(¿ï»ê´ëÇб³) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ16:00~16:30 Experiences to Characterize Exposure-Response Relationship for Various Therapeutics using Modeling and Simulation: Advantages and Challenges  ÇѼºÇÊ(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ16:30~17:00 Exposure-Response RelationshipÀ» ÀÌ¿ëÇÑ ½Å¾à°³¹ß °æÇè  ÀÌÁöÀº(LG »ý¸í°úÇÐ) 
Åä·Ð 04-29 ¿Â¶óÀΠ17:00~17:20 Åä·Ð  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2022-04-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ½ÉÀå´ë»çÁõÈıºÇÐȸ 2022 5th APCMS (Asia-Pacific CardioMetabolic Syndrome) CONGRESS(1ÀÏÂ÷) : 2022-04-29
´ÙÀ½±Û (¿Â¶óÀÎ) ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­¿ï µ¿ºÎÁöȸ ¿ù·ÊÁý´ãȸ : 2022-04-28
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
510 ¼­¿ï °­µ¿¼º½Éº´¿ø °­µ¿±¸ÀÇ»çȸ Á¦4Â÷ ¿¬¼ö±³À° : 2018-09-10 0 916 2018-08-22
509 ¼­¿ï »ýÈ° ¼Ó ¹æ»ç¼± ±¦ÂúÀ»±î¿ä / ³­¼Ò¾ÏÀÇ Ä¡·á : 2018-09-10 0 593 2018-08-22
508 ¼­¿ï 2018 ´ëÇÑÅëÁõ¿¬±¸ÇÐȸ Ãß°è Çмú´ëȸ : 2018-09-09 0 580 2018-08-22
507 ´ë±¸ ¿µ³²´ëÇб³º´¿ø Á¦30Â÷ ´ëÇÑÅõ¼®Ç÷°üÇÐȸ ÇÏ°èÇмú´ëȸ : 2018-09-09 0 986 2018-08-22
506 °­¿ø ¿øÁÖÀÇ°ú´ëÇÐ 2018³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ °­¿øÁöȸ ¿¬¼ö°­Á : 2018-09-09 0 616 2018-08-22
505 ¼­¿ï ¼­¿ï¼º¸ðº´¿ø ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ Á¦2ȸ ¹Ì·¡Æ÷·³ : 2018-09-08 0 1,091 2018-08-22
504 ¼­¿ï 2018³â Á¦ 9ȸ ¼­¿ï¾Æ»êº´¿ø ±¹¸³º¸°Ç¿¬±¸¿ø ¾Ë·¹¸£±âÁúȯ ¿ªÇÐ ½ÉÆ÷Áö¾ö : 2018-09-08 0 654 2018-08-22
503 °æ³² â¿ø °æ»ó´ëÇб³º´¿ø °æ³²°³¿ø³»°úÀÇ»çȸ Ãß°èÇмú´ëȸ : 2018-09-08 0 1,363 2018-08-22
502 ±¤ÁÖ Á¦169Â÷ ´ëÇѼҾưúÇÐȸ ±¤ÁÖ¡¤Àü³²Áöȸ ÇмúÁý´ãȸ : 2018-09-08 0 900 2018-08-22
501 ¼­¿ï °¡Å縯ÀÇ´ë(¼­¿ï¼º¸ðº´¿ø) 2018 ´ëÇÑ°¨¿°ÇÐȸ Àü°øÀÇ¿Í Àü¹®ÀǸ¦ À§ÇÑ Ãß°è °¨¿°ÇÐ ¿¬¼ö°­Á : 2018-09-08 0 468 2018-08-22
500 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø À¯¹æ¼ºÇü¿¬±¸È¸ 3Â÷ ½ÉÆ÷Áö¿ò : 2018-09-08 1 826 2018-08-22
499 ºÎ»ê Á¦7ȸ ºÎ¹Îº´¿ø ½½°üÀý ½ÉÆ÷Áö¾ö(´ëÇѽ½°üÀýÇÐȸ, ºÎ¹Îº´¿ø °øµ¿ÁÖ°ü) : 2018-09-08 0 1,563 2018-08-22
498 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø 2018 ¾Æ»ê ÇÙÀÇÇÐ ½ÉÆ÷Áö¾ö : 2018-09-08 0 593 2018-08-22
497 ¼­¿ï °æÈñ´ëÇб³º´¿ø 2018 KYUNG HEE SHOULDER SYMPOSIUM : 2018-09-08 0 1,504 2018-08-22
496 ´ë±¸ °æºÏ´ëÇб³º´¿ø Á¦ 3Â÷ °³¿øÀǸ¦ À§ÇÑ ´ëÇѺÎÁ¤¸ÆÇÐȸ ¿¬¼ö±³À° : 2018-09-07 0 742 2018-08-22
1361 | 1362 | 1363 | 1364 | 1365 | 1366 | 1367 | 1368 | 1369 | 1370
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷